Clinical Trials Logo

Filter by:
NCT ID: NCT05827016 Recruiting - Multiple Myeloma Clinical Trials

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Start date: June 22, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

NCT ID: NCT05826444 Recruiting - Clinical trials for Cardiac Allograft Vasculopathy

Microvascular Cardiac Allograft Vasculopathy Trial

mCAV
Start date: October 1, 2022
Phase:
Study type: Observational

The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT). The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis.

NCT ID: NCT05826353 Recruiting - Clinical trials for Fuchs Endothelial Corneal Dystrophy

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Start date: May 11, 2023
Phase: Phase 3
Study type: Interventional

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

NCT ID: NCT05825625 Recruiting - Clinical trials for Non-small Cell Lung Cancer

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.

NCT ID: NCT05824117 Recruiting - Schizophrenia Clinical Trials

Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.

SEEearly
Start date: October 18, 2022
Phase: N/A
Study type: Interventional

Psychotic disorders often develop a chronic course with devastating consequences for individuals, families, and societies usually with first onset during adolescence and early adulthood. Early intervention programs, which provide intensive, phase specific, psychosocial, and pharmacological treatment for people in the first five years after the initial psychotic episode (early psychosis) can significantly improve the outcome and are therefore strongly recommended in national and international guidelines. However, most early intervention programs in people with early psychosis still focus on improving symptoms and relapse prevention, rather than targeting educational and vocational recovery, although engagement in work and education is a high priority for young people with early psychosis and reduces the social disability associated with the disorder. The aim of the present study is to explore the effects of Supported Employment and Education (SEE) following the Individual Placement and Support (IPS) model in people with early psychosis. The investigators compare treatment as usual (TAU) in an outpatient psychiatric setting to TAU plus SEE.

NCT ID: NCT05822908 Recruiting - Huntington Disease Clinical Trials

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Start date: February 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

NCT ID: NCT05822583 Recruiting - COVID-19 Clinical Trials

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Start date: July 6, 2023
Phase: Phase 4
Study type: Interventional

COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.

NCT ID: NCT05821920 Recruiting - Clinical trials for Degenerative Disc Disease

A Safety Study on Posterior Pedicle Screw System

MUST MINI PMS
Start date: June 28, 2021
Phase:
Study type: Observational

The goal of this study is to assess the MUST MINI system safety in patient who will undergo a posterior cervical spine fusion intervention. Patients will be invited to partecipate during preoperative visit and follow the postoperative visits according to the standard practice.

NCT ID: NCT05821660 Recruiting - Healthy Lifestyle Clinical Trials

Fastreset Study: Metabolic Effects of a Five-day Remotely Delivered Hypocaloric and Ketogenic Program

Fastreset
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to assess changes in body and metabolism caused by this new five-day hypocaloric and ketogenic programme

NCT ID: NCT05821166 Recruiting - Oncology Clinical Trials

Potential of Moderate Whole Body Hyperthermia to Enhance Response

POWER
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment